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Objective The illicit recreational drug 3,4-methylenedioxymethamphetamine (MDMA) or Ecstasy has strong neurohormonal effects. When taken
by recreational users at dance clubs and raves, it can generate an 800% increase in the stress hormone cortisol, whereas drug-free users show chron-
ically raised levels of cortisol. The aim here is to critically debate this neurohormonal inﬂuence for the children of pregnant MDMA-using mothers.
Methods High levels of cortisol are known to be damaging for neuropsychobiological well-being in adult humans. MDMA can damage
foetal development in laboratory animals, and the prospective Drugs and Infancy Study was established to monitor the effects of MDMA
taken recreationally by pregnant women.
Results The Drugs and Infancy Study revealed that young mothers, who took MDMA during the ﬁrst trimester of pregnancy, gave birth to
babies with signiﬁcant gross psychomotor retardation . These mothers would have experienced high levels of cortisol due to Ecstasy/MDMA
use, and since cortisol can cross the placenta, this is likely to have also occurred in the foetus.
Conclusions In terms of causation, the developmental problems may reﬂect a combination of neurotransmitter and neurohormonal effects
on the hypothalamic–pituitary–adrenal axis, with serotonergic activity being inﬂuenced by the high levels of cortisol. Copyright © 2014 John
Wiley & Sons, Ltd.
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MDMA: A BRIEF INTRODUCTION TO
‘ECSTASY’
3,4-Methylenedioxymethamphetamine (MDMA) or
‘Ecstasy’ is used as an illicit recreational drug, by
minority subgroups of adolescents and young adults
(Parrott, 2001; Singer et al., 2004). MDMA is a ring-
substituted methamphetamine derivative with many
similarities to the parent compound. It has a particular
afﬁnity for the serotonin transporter (SERT) and can
release up to 80% of available serotonin, but like
methamphetamine, it also stimulates the release of
dopamine and other neurotransmitters (Ricaurte et al.,
2000; Green et al., 2003). MDMA is a powerful central
nervous system stimulant, which can lead to psycho-
physiological overstimulation and various aspects of
the serotonin syndrome (Parrott, 2002). Its acute effects
typically include euphoria, although it can also lead to
feelings of anxiety and mental confusion (Cohen,
1998; Parrott et al., 2011; Kirkpatrick et al., 2012). In
recreational users at dance clubs, its use often leads to
overheating and physical exhaustion (Suy et al., 1999;
Moreﬁeld et al., 2009; Parrott, 2012a), with occasional
medical complications, which can prove fatal if not
treated rapidly (Hall and Henry, 2006; Schifano et al.,
2006; Greene et al., 2009).
In laboratory animals, MDMA is a serotonergic
neurotoxin (Ricaurte et al., 1985, 2000), with the
extent of neuronal damage heightened by environmental
conditions, which necessitate further energy expenditure
(Huether et al., 1997; Malberg and Seiden, 1998;
Sanchez et al., 2004; Puerta et al., 2009). In abstinent
recreational users, neuroimaging procedures such as
positron emission tomography and functional magnetic
resonance imaging have revealed lower levels of the
SERT across all regions of the cerebral cortex, with
the degree of serotonin loss correlating with lifetime
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Ecstasy/MDMA usage (Reneman et al., 2006; Cowan,
2007; Kish et al., 2010; Erritizoe et al., 2011). The
functional problems of drug-free recreational users can
include memory loss, impaired cognitive awareness,
reduced problem solving skills, lower social intelligence
and various forms of psychiatric distress (Schifano et al.,
1998; Topp et al., 1999; Fox et al., 2001, 2002; Parrott
et al., 2001; Roiser and Sahakian, 2004; Singer et al.,
2004; Soar et al., 2004; Parrott, 2006, 2012b, 2013a,
2013b; Reay et al., 2006; Zakzanis and Campbell,
2006; McCann and Ricaurte, 2007; Montgomery et al.,
2010; Brière et al., 2012; Benningﬁeld and Cowan,
2013). Abstinent Ecstasy/MDMA users also report
feeling signiﬁcantly more stressed in their daily lives
than non-user controls (Scholey et al., 2011) and feel
less calm when undertaking a standard laboratory stress
task (Wetherell et al., 2012).
DRUGS AND INFANCY STUDY: PROSPECTIVE
EFFECTS OF MDMA IN PREGNANCY
Animal laboratory research has shown that MDMA can
damage foetal development. A review of the preclinical
literature has implicated MDMA exposure, in the period
equivalent to the ﬁrst or third trimester, with deﬁcits in
long-term memory, learning and loco-motor activity
(Skelton et al., 2008). These preclinical ﬁndings raise
concerns about the potentially damaging effects in preg-
nant women. The Drugs and Infancy Study (DAISY)
was undertaken to empirically investigate this question.
We prospectively monitored 28 women who took
MDMA during pregnancy and compared them with a
polydrug control group of 68 women who took other
psychoactive drugs while pregnant. The drug usage pat-
terns for these mothers have been summarised byMoore
et al. (2010), the birth and 4-month child outcome ﬁnd-
ings are described by Singer et al. (2012a), the 12-month
child proﬁles by Singer et al. (2012b) and the 24-month
outcomes by Singer et al. (2013). The main ﬁnding was
a signiﬁcant delay in psychomotor development in the
children of Ecstasy/MDMA-using mothers (Table 1).
This was found at the 4, 12 and 24-month assessment
batteries, and the degree of psychomotor deﬁcit was
positively associated with greater MDMA usage during
the ﬁrst trimester (Singer et al., 2012a, 2012b). Two
European medical studies found a higher incidence of
congenital malformations, in the births of mothers who
had used MDMA while pregnant (van Tonningen-van
Driel et al., 1999; McElhatton et al., 1999; Table 1).
In terms of causation, one potential explanation for
the psychomotor differences is MDMA-induced ‘sero-
tonergic neurotoxicity’ in the developing neonatal brain.
In support of this serotonergic explanation, Jacobs and
Fornal (1995) noted in a serotonin review that one of
the functions it modulated was gross psychomotor
control. However, cortisol may also be involved, as rec-
reational Ecstasy/MDMA users can show pronounced
changes in this core neurohormone. Reynolds (2013)
reported that high levels of cortisol could have a range
of adverse effects during human pregnancy, although
psychobiological problems in the emergent children
were also noted in an earlier review (Van den Bergh
et al., 2005). Hence, cortisol may have some directly
damaging effects on foetal development in humans.
Furthermore, as cortisol is known to inﬂuence serotonin
activity (Chaouloff, 2000), it may also contribute indi-
rectly to serotonergic neurotoxicity.
CORTISOL AND MDMA
Selye (1956) revealed the crucial role of cortisol for
homeostasis and psychophysiological stability. Under
conditions of high energy demand, the capacity for
metabolic stability could be overloaded, and the general
adaptation syndrome was initiated. This comprised an
integrated set of neurohormonal and physiological
reactions, including cortisol release, which helped to
provide the additional metabolic resources necessary
for continued functioning (Lovallo, 1997). Selye's
research was primarily focused on physical stressors,
such as hot and cold environments, anoxia at high
altitudes and marathon running. The physical nature of
biological stress is particularly relevant here, as MDMA
is typically taken under physically demanding condi-
tions. Dance clubs are often overcrowded, with high
ambient temperatures, and dancing can be both
energetic and prolonged. Suy et al. (1999) described
one large Dutch rave, where most visits to the paramedic
centre involved Ecstasy/MDMA users who were feeling
overheated or physically exhausted. After rest, cooling
and ﬂuid replacement, many returned to the dance ﬂoor.
In placebo-controlled laboratory studies, MDMA can
generate a dose-related increase in core body temperature
in humans (Freedman et al., 2005; see summary table in
Parrott, a). Dance clubbers may demonstrate even greater
increases in body temperatures, with group mean peak
changes of over 1.0 °C, although these thermal effects
can be variable (Parrott and Young, 2005; Parrott et al.,
2006, 2007; Moreﬁeld et al., 2009). As this recreational
drug is typically used in physically stressful conditions
(Suy et al., 1999; Parrott, 2004), it is probably the
combined effects of sympathomimetic drug and environ-
mental co-stimulation, which make MDMA damaging
for human psychobiology (Parrott, 2002, 2004, 2006).
For instance, Darvesh and Gudelsky (2005) noted that
‘MDMA produces a dysregulation of energy metabolism
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which contributes to the mechanism of MDMA induced
neurotoxicity’.
The effects of acute MDMA on cortisol have been
investigated in several placebo-controlled laboratory
studies. Mas et al. (1999) found a signiﬁcant increases
in cortisol after 75 and 125-mg oral MDMA. Similar
increases in cortisol were noted by Paciﬁci et al.
(1999, 2001). In percentage terms, Harris et al. (2002)
reported that 0.5mg/kg MDMA led to a cortisol increase
over baseline of around 100%, whereas the higher dose of
1.5mg/kg led to percentage increase of 150% over base-
line. In their MDMA review, Dumont and Verkes (2006)
concluded that acute drug administration led to a robust
cortisol increase. Cortisol is also heightened after recrea-
tional Ecstasy/MDMA self-administration in dance clubs
or house parties (Table 1). In the work of Parrott et al.
(2008), Ecstasy/MDMA users were assessed on
successive weekends when partying on-drug as usual
and when partying while abstaining fromMDMA. Saliva
samples conﬁrmed MDMA presence during the on-drug
weekend and its absence during the abstinence week-
end (Parrott et al., 2008). The combination of dance
clubbing and recreational Ecstasy/MDMA led to a
group mean 800% increase in saliva cortisol, signiﬁ-
cantly higher than both baseline and clubbing during
abstinence (Table 2). In a related study, experienced
Ecstasy users were assessed at a ‘house party’, where
self-reported Ecstasy/MDMA use ranged from 2 to 9
tablets per individual (Parrott et al., 2007). Cortisol
levels were again increased by 800% after 4 h on
self-administered Ecstasy/MDMA, whereas cortisol
levels while partying without MDMA were
statistically unchanged (Table 2).
In chronic terms, abstinent recreational Ecstasy/MDMA
users also show signiﬁcant neurohormonal changes. Gerra
et al. (1998) found a reduced cortisol response to a
d-fenﬂuramine challenge in drug-free recreational
MDMA users. This was empirically replicated in a
follow-up study by the same group (Gerra et al.,
2000). Verkes et al. (2001) also found a signiﬁcant
reduction in cortisol responses to a d-fenﬂuramine
challenge, in both moderate and heavy abstinent
Ecstasy/MDMA users. Gerra et al. (2003) further
noted that baseline cortisol levels were signiﬁcantly
lower in abstinent Ecstasy users; they also demon-
strated a reduced cortisol response to a psychosocial
stressor. The authors concluded that there was em-
pirical evidence for ‘hypothalamic–pituitary–adrenal
(HPA) basal hyperactivation and reduced respon-
siveness to stress, which may represent a complex
neuroendocrine dysfunction associated with MDMA
use’. More recently, hair samples from +100 partic-
ipants in Wales were analysed at Dresden Univer-
sity for cumulative 3-month cortisol levels (Parrott
et al., 2012). Recent light Ecstasy/MDMA users
(1–4 occasions in the past 3months) had a group
mean 50% elevation of cortisol levels, compared with
non-user controls. Recent heavier Ecstasy/MDMA
users (+5 occasions in past 3months) displayed a
group mean 400% increase in hair cortisol. They also
displayed poorer cognitive performance, with fewer
words recalled, and more self-rated memory problems
(Table 3). This is consistent with empirical evidence
that high levels of cortisol are associated with various
neurocognitive deﬁcits, including poorer memory
across all stages of the lifespan (Lupien et al., 2005).
Furthermore, these high 3-month cortisol values suggest
that regular Ecstasy/MDMA users experience both HPA
axis overactivity and enduring psychobiological stress.
Table 1. Overview of human studies into the effects of recreational Ecstasy/3,4-methylenedioxymethamphetamine (MDMA) taken during pregnancy
on birth outcomes
Study Summary of methods and main ﬁndings
McElhatton et al. (1999) ‘Prospective follow-up of 136 babies exposed to ecstasy in utero indicated that the drug may be associated with
a signiﬁcantly increased risk of congenital defects’. Cardiovascular anomalies and musculoskeletal anomalies
were predominant.
Van Tonningen-van Driel et al. (1999) Monitored 43 case studies of Ecstasy/MDMA exposure early in pregnancy, in the Netherlands. One incidence
of a congenital cardiac abnormality. Authors concluded that ‘The sample size was too small to draw
conclusions’.
Singer et al. (2012a) DAISY of 96 women in the UK, with 28 MDMA exposed and 68 control group mothers. Prospectively
monitored from early pregnancy to 2 years post-partum. This report covers the neonatal ﬁndings 4months
post-partum. ‘MDMA exposed infants… had poorer motor quality and lower milestone attainment at
4months, with a dose-response relationship to amount of MDMA exposure’.
Singer et al. (2012b) Infants from DAISY study 12months post-partum. Standard assessments for cognitive, language and
psychomotor functioning. It was found that ‘Amount of prenatal MDMA exposure predicted poorer infant
mental and motor development at 12months in a dose-dependent manner’.
Singer et al. (2013) DAISY study at 24months post-partum, with signiﬁcant psychomotor problems still present In overall terms:
‘Prenatal MDMA exposure predicts poorer motor outcomes from 4months to 2 years of age. Given the
widespread recreational use of MDMA (Ecstasy), pregnant women should be cautioned about possible
developmental effects in offspring’.
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The mothers in our DAISY, who were also regular users
of Ecstasy/MDMA, may therefore have experienced
similar high levels of cortisol and stress.
CORTISOL DURING PREGNANCY AND FOETAL
DEVELOPMENT
Any increase in maternal cortisol may be an adverse
impact on the developing foetus. Cortisol is involved in
the neurohormonal stress, and increased levels of
maternal stress during pregnancy are associated with
many sub-optimal developmental outcomes. In animal
studies, the offspring of prenatally stressed mothers show
increased anxiety and reduced attention span (Schneider
et al., 2001). They also show differences in brain struc-
ture, including changes in hippocampal volume and other
areas (Coe et al., 2003). In human infants, heightened
stress during pregnancy is associated with several adverse
physical effects, including low birth-weight, reduced
head circumference, low Agpar scores and other short-
term/long-term developmental issues. Reviews of the
literature (Van den Bergh et al., 2005) have concluded
that ante-natal stress can lead to signiﬁcant long-term
regulation problems in human infants. This can be
manifest at cognitive, behavioural and emotional levels,
with infants showing higher reactivity in interactions with
their mothers, poorer attention, lower maternally-reported
language ability, sleeping, feeding and activity problems,
and higher ratings for irritability and being difﬁcult.
When the children reach pre-school years, it has been
found that those who were exposed to stress in utero
showed poorer attention, greater hyperactivity, emotional
problems and more behavioural difﬁculties. In the longer
term, these children and adolescents may show greater
impulsivity, reduced IQ and a greater prevalence of
Attention Deﬁcit Hyperactivity Disorder (Van den Bergh
et al., 2005). Reynolds (2013) similarly noted that high
levels of maternal cortisol were associated with adverse
outcomes in their children, including behavioural disor-
ders and altered brain structure.
The mechanisms underlying the transmission of the
effects of stress from the mother to the developing in-
fant are not fully understood, but one hypothesis is that
maternal stress hormones and particularly glucocorti-
coids are transmitted across the placenta. Singh et al.
(2012) noted that ‘Maternal stress during pregnancy
can raise endogenous levels of the natural glucocorti-
coid cortisol. A signiﬁcant proportion of the cortisol
is inactivated by the placental glucocorticoid barrier’,
although some cortisol still reaches the developing
foetus. These neurohormones may then re-programme
the HPA reactivity of the infant, with a range of
subsequent adverse outcomes. There is debate about
the extent to which core psychobiological processes
Table 3. Cortisol levels and cognitive assessments for recent light Ecstasy/3,4-methylenedioxymethamphetamine (MDMA) users, recent heavy Ecstasy/
MDMA users, and non-users controls
Non-user controls (no MDMA usage) Recent light users (1–4 MDMA times) Recent heavy users (5+ MDMA times)
Cortisol (3-month hair) 13.78 (6.09) 19.37 (15.96) 55.01 (80.13)*
Hassles (self-rated) 4.63 (3.58) 5.25 (4.75) 7.48 (3.64)*
Cognitive failures (self-rated) 4.87 (4.22) 5.97 (5.26) 8.17 (4.14)*
Memory problems (self-rated) 4.26 (3.94) 5.72 (5.5) 7.91 (4.24)*
Rivermead: delayed word recall 6.83 (3.48) 4.25 (3.24)* 4.91 (1.98)*
Drug usage and cortisol hair sampling from the previous 3-months (after Parrott et al., 2012).
Table 2. Cortisol levels for two studies of recreational Ecstasy/3,4-methylenedioxymethamphetamine (MDMA) users before, during and after dance clubbing
or partying (means and standard errors)
Study 1 Pre-drug baseline 1-h post-drug 2.5-h post-drug 48-h post-drug 72-h post-drug
On MDMA 0.3 +0.3 0.9 +0.5*** 2.2 +1.1*** 0.5 +0.7 0.4 +0.5
Abstinence 0.2 +0.1 0.2 +0.2 0.4 +0.4 0.4 +0.4 0.2 +0.2
Study 2 Pre-drug baseline 2-h post-drug 4-h post-drug 6-h post-drug 24-h post –drug
On MDMA 0.3 +0.1 1.0 +0.7* 2.3 + -0.3*** 1.5 +0.9** 0.7 +0.6+
Abstinence 0.3 +0.3 0.4 +0.3 0.3 +0.2 0.5 +0.8 0.4 +0.5
Each participant was assessed on self-administered MDMA, and off-MDMA, over counterbalanced weekends at the same dance club. Signiﬁcance levels rep-
resent comparisons with pre-drug baseline (studies 1 and 2 after Parrott et al., 2007, 2008).
Paired comparisons with pre-drug baseline.
*p< 0.05.
**p< 0.01.
***p< 0.001.
4 a. c. parrott ET AL.
Copyright © 2014 John Wiley & Sons, Ltd. Hum. Psychopharmacol Clin Exp 2014; 29: 1–7.
DOI: 10.1002/hup
and speciﬁcally HPA re-programming may be respon-
sible for these stress effects. However, there is cer-
tainly evidence that an increase in maternal cortisol
level can lead to a corresponding, but not directly
equivalent, increase in levels of foetal cortisol. One
source of uncertainty is the extent to which this effect
is large enough and immediate enough to explain all
adverse psychobiological outcomes. Typically, an in-
crease in maternal cortisol of 10% in the mother is as-
sociated with a corresponding increase across the
placenta of around 1% in the infant, with this change
occurring after a delay of around 10min.
Given that recreational MDMA leads to an 800% in-
crease in cortisol 4 h after taking the drug and that reg-
ular users register a 400% increase over the 3-month
period (Parrott et al., 2008, 2012), there may be
signiﬁcant risks of heightened cortisol in the foetus
of an Ecstasy/MDMA-using mother (Singer et al.,
2012a, 2012b). Furthermore, the 3-month data suggest
that there may be a risk of increased cortisol for the
developing foetus, in those mothers who quit using
immediately before pregnancy. Sustained exposure is
also more likely to have a detrimental impact than
more ﬂeeting exposures, although the strength of the
acute neurohormonal reaction to MDMA should be
noted. The main concern is that with regular recrea-
tional Ecstasy/MDMA usage, cortisol levels will be
increased, both acutely and chronically. The adverse
consequences of these neurohormonal changes for the
developing foetus may be broadly similar to those
found with other forms of maternal stress.
OVERVIEW: CORTISOL, MDMA AND
PREGNANCY
The DAISY found that heavier recreational Ecstasy/
MDMA use during the ﬁrst trimester of pregnancy led
to signiﬁcant developmental differences in the emergent
children (Singer et al., 2012a, 2012b). The main area of
difﬁculty was in gross psychomotor functioning, with
the other assessed areas being unaffected. For the upper
half of the sample whose infants demonstrated motor
effects, MDMA usage averaged 3.3 ± 4.0 tablets per
week in the month prior to pregnancy. The extent of
the psychomotor differences was also associated with
cumulative Ecstasy/MDMA usage during the ﬁrst
trimester. However, it is still not clear which underlying
factors are causing these deﬁcits. One potential explana-
tion is serotonergic neurotoxicity. Neuroimaging studies
have found that MDMA is associated with reduced levels
of the SERT, whereas cumulative-lifetime drug usage
correlates with the lower levels of SERT (McCann et al.,
2008; Kish et al., 2010). This leads to the hypothesis that
the neonatal brain is being adversely affected, in a way
similar to the mother's brain. Another potential explana-
tion is neurohormonal, with heightened bio-energetic
stress disrupting normal HPA axis activity and everyday
homeostasis. This explanatory model for MDMA is
outlined more fully by Parrott (2009), where it was noted
that both high and low levels of cortisol can impair
various neuropsychobiological functions, including
memory, sleep, brain integrity and psychiatric well-
being (Herbert et al., 2007).
As outlined previously, Van den Bergh et al. (2005)
reported that ‘cortisol appears to cross the placenta’.
Hence, high levels of cortisol in Ecstasy/MDMA-using
mothers may have generated signiﬁcant cortisol
increases in the developing foetus (also: Singh et al.,
2012). The bio-energetic stress of recreational Ecstasy/
MDMA in pregnant women may thus lead to bio-
energetic stress, impaired homeostasis and developmen-
tal difﬁculties in the developing foetus. It should be
emphasised that MDMA usage in the DAISY ceased
almost entirely after the ﬁrst trimester (Moore et al.,
2010), so that any increase in cortisol would largely be
limited to that period. However, there may be some
residual increases in cortisol, which continue into the
next trimester. It should be noted that the neurotransmit-
ter and neurohormonal explanations are not alternatives,
but different aspects of the same underlying bio-
energetic stress model. Serotonin and cortisol are
closely interlinked (Chaouloff, 2000), with both being
involved in neuropsychobiological integrity. Herbert
et al. (2007) noted that ‘Corticosteroids are an essen-
tial component of the body's homeostatic system’.
MDMA stimulates the release of cortisol in both the
laboratory (Harris et al., 2002) and at the dance clubs
(Table 1). Hence, pregnant women who take Ecstasy/
MDMA will experience profound changes in both
cortisol and general neuropsychobiological integrity.
Their homeostatic status may be impaired, and this will
often occur at night when they would normally experi-
ence recuperating sleep. Cortisol is an important factor
for acute bio-energetic stress, whereas in chronic terms,
it can help explain the damaging effects of regular
Ecstasy/MDMA usage. These neuropsychobiological
effects may reﬂect a combination of factors, both
hormonal and neural. Together they can produce an
enduring period of homeostatic disruption and bio-
energetic stress. Hence, it is not too surprising that
child development can be adversely affected by
recreational MDMA usage in the mother (Table 1).
A ﬁnal issue raised by these ﬁndings is the
importance of publicising the need for women to
abstain from drug-taking if there is any possibility of
pregnancy. There is also a need for several months of
5mdma, cortisol and pregnancy outcomes
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abstinence beforehand, to facilitate a return to normal
neurohormonal levels. This paper has focused on the
adverse effects of Ecstasy/MDMA, but other stimulants
such as cocaine and amphetamine are also damaging,
as are psychoactive drugs such as cannabis, nicotine
and alcohol. The HPA axis needs to be stable prior to
conception and hence should not be disrupted by drug
stressors. It is crucially important to protect the devel-
oping foetus from the potentially damaging effects of
neurohormonal instability (Glover, 2011).
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